WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206004
Description: Tezacitabine is a synthetic purine nucleoside analogue with potential antineoplastic activity. Phosphorylated by cellular kinases, tezacitabine is converted into its active diphosphate and triphosphate metabolites. Tezacitabine diphosphate binds to and irreversibly inhibits the activity of the enzyme ribonucleotide reductase (RNR), which may result in the inhibition of DNA synthesis in tumor cells and tumor cell apoptosis. Tezacitabine triphosphate acts as a substrate for DNA polymerase, further compromising DNA replication.
MedKoo Cat#: 206004
Chemical Formula: C10H11FN2O4
Exact Mass: 242.07029
Molecular Weight: 242.2
Elemental Analysis: C, 49.59; H, 4.58; F, 7.84; N, 11.57; O, 26.42
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: MDL 101731; FMdC; KW 2331; MDL 101731; KW2331; MDL101731;
IUPAC/Chemical Name: 1-((2R,4S,5R,E)-3-(fluoromethylene)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
InChi Key: CXVQYURZKMJITE-JZUREZDFSA-N
InChi Code: InChI=1S/C10H11FN2O4/c11-4-6-8(15)7(5-14)17-9(6)13-3-1-2-12-10(13)16/h1-4,7-9,14-15H,5H2/b6-4+/t7-,8+,9-/m1/s1
SMILES Code: O=C1N=CC=CN1[C@@H]2O[C@H](CO)[C@@H](O)/C2=C\F
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 242.2 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Taverna P, Rendahl K, Jekic-McMullen D, Shao Y, Aardalen K, Salangsang F, Doyle L, Moler E, Hibner B. Tezacitabine enhances the DNA-directed effects of fluoropyrimidines in human colon cancer cells and tumor xenografts. Biochem Pharmacol. 2007 Jan 1;73(1):44-55. Epub 2006 Sep 16. PubMed PMID: 17046720.
2: Skierski JS, Koronkiewicz M, Grieb P. Tezacitabine blocks tumor cells in G1 and S phases of the cell cycle and induces apoptotic cell death. Acta Pol Pharm. 2005 May-Jun;62(3):195-205. PubMed PMID: 16193812.
3: Stachnik K, Grieb P, Skierski JS. Cytotoxic effects of cladribine and tezacitabine toward HL-60. Acta Biochim Pol. 2005;52(2):561-5. Epub 2005 May 31. PubMed PMID: 15933759.
4: Bendell JC, Eder JP, Clark JW, Fidias P, Lynch TJ, Seiden MV, Ryan DP. Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors. Cancer. 2005 May 1;103(9):1925-31. PubMed PMID: 15772958.
5: Flaherty KT, Stevenson JP, Gallagher M, Giantonio B, Algazy KM, Sun W, Haller DG, O'Dwyer PJ. Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer. Cancer. 2003 Apr 15;97(8):1985-90. PubMed PMID: 12673728.
6: Rodriguez GI, Jones RE, Orenberg EK, Stoltz ML, Brooks DJ. Phase I clinical trials of tezacitabine [(E)-2'-deoxy-2'-(fluoromethylene)cytidine] in patients with refractory solid tumors. Clin Cancer Res. 2002 Sep;8(9):2828-34. PubMed PMID: 12231523.
7: Seley KL. Tezacitabine Hoechst Marion Roussel. Curr Opin Investig Drugs. 2000 Sep;1(1):135-40. Review. PubMed PMID: 11249589.